Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Gliosarcoma 5Glioblastoma 5Gastrointestinal Stromal Tumors 5Sarcoma 3Brain Neoplasms 3Rhabdomyosarcoma 2Oligodendroglioma 2Glioma 2Central Nervous System Neoplasms 2Astrocytoma 2Wilms Tumor 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinal Cord Neoplasms 1Solitary Fibrous Tumors 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdoid Tumor 1Recurrence 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nephroma, Mesoblastic 1

Interventions

Vinorelbine 2Vincristine 2Radiotherapy 2Radiation 2Dactinomycin 2Cyclophosphamide 2temsirolimus 1ganitumab 1efineptakin alfa 1dinutuximab 1X-Rays 1TB-403 1Specimen Handling 1Sirolimus 1Saline Solution 1Receptor Protein-Tyrosine Kinases 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Irinotecan 1Dasatinib 1Crizotinib 1Biopsy 1Biological Factors 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Alveolar × Dasatinib × Sarcoma × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡